FORUM meeting at LV Prasad Eye Institute.

Hyderabad, 01 August 2018

A two day FORUM Glaucoma Workplace and Retina Workplace application training with Hands-on workshop was conducted for consultants and optometrist at LV Prasad Eye Institute, Hyderabad by ZEISS India. More than 50 consultants from LVPEI participated in this two day workshop.

 

The program was ideated by Dr. G Chandra Sekhar, Vice-chair, LVPEI, who felt the need for consultants and care-givers to be updated on the latest advancements and its best utilization for giving the highest level of patient care. Dr. Rajeev Reddy, Head-patient care services at LVPEI, also expressed to have such engagement on regular basis to enable patient care excellence.

“The training helped better understanding of the FORUM platform and advances in the integration of the imaging and HFA for better patient management” said Dr Sirisha Senthil, Head - Glaucoma care at LVPEI.

Contact: 

Dr. Jochen Tham
Head of Marketing Communications
Carl Zeiss Meditec AG
Phone: +49 (0)7364 206-756
E-mail: press .meditec @zeiss .com

Brief profile Carl Zeiss Meditec AG:

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,000 employees worldwide, the Group generated revenue of €1,189.9m in fiscal year 2016/17 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at: www.zeiss.com/med